Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 3, 2011, Pages 1063-1067

  Grönlund, Juha ^a   Saari, Teijo I ^a   Hagelberg, Nora ^a   Neuvonen, Pertti J ^b   Olkkola, Klaus T ^a   Laine, Kari ^c  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DRUG METABOLITE; MICONAZOLE; MUNDIPHARMA; NOROXYCODONE; NOROXYMORPHONE; OXYCODONE; OXYMORPHONE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CROSSOVER PROCEDURE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXPOSURE; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; GEL; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; PAIN THRESHOLD; PATIENT COMPLIANCE; PRIORITY JOURNAL; PUPIL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; ANALGESICS, OPIOID; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; FEMALE; HUMANS; MALE; MICONAZOLE; OXYCODONE; PAIN; YOUNG ADULT;

EID: 79952356988     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01242-10     Document Type: Article

References (28)

1. Ariyaratnam, S., N. S. Thakker, P. Sloan, and M. H. Thornhill. 1997. Potentiation of warfarin anticoagulant activity by miconazole oral gel. BMJ 314:349.
2. Bond, A., and M. Lader. 1974. Use of analog scales in rating subjective feelings. Br. J. Med. Psychol. 47:211-218.
3. Cogan, D. G. 1941. Simplified entopic pupillometer. Am. J. Ophthalmol. 24:1431-1433.
4. Compas, D., D. J. Touw, and P. N. de Goede. 1996. Rapid method for the analysis of itraconazole and hydroxyitraconazole in serum by high-performance liquid chromatography. J. Chromatogr. B Biomed. Appl. 687:453-456.
5. Daneshmend, T. K., and D. W. Warnock. 1983. Clinical pharmacokinetics of systemic antifungal drugs. Clin. Pharmacokinet. 8:17-42.
6. Devaraj, A., J. P. O'Beirne, R. Veasey, and A. A. Dunk. 2002. Interaction between warfarin and topical miconazole cream. BMJ 325:77.
7. Dhalla, I. A., et al. 2009. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. Can. Med. Assoc. J. 181:891-896.
8. Grönlund, J., et al. 2010. Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br. J. Clin. Pharmacol. 70:78-87.
9. Hagelberg, N. M., et al. 2009. Voriconazole drastically increases exposure to oral oxycodone. Eur. J. Clin. Pharmacol. 65:263-271.
10. Hamunen, K., P. Paakkari, and E. Kalso. 2009. Trends in opioid consumption in the Nordic countries 2002-2006. Eur. J. Pain 13:954-962.
11. Hynninen, V. V., K. T. Olkkola, P. J. Neuvonen, and K. Laine. 2009. Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. Eur. J. Clin. Pharmacol. 65:89-95.
12. Kato, M. 2008. Intestinal first-pass metabolism of CYP3A4 substrates. Drug Metab. Pharmacokinet. 23:87-94.
13. Lalovic, B., et al. 2006. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin. Pharmacol. Ther. 79:461-479.
14. Lalovic, B., B. Phillips, L. L. Risler, W. Howald, and D. D. Shen. 2004. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab. Dispos. 32:447-454.
15. Männistä, P. T., R. Mäntylä, S. Nykänen, U. Lamminsivu, and P. Ottoila. 1982. Impairing effect of food on ketoconazole absorption. Antimicrob. Agents Chemother. 21:730-733.
16. Martinez-Beneyto, Y., P. Lopez-Jornet, A. Velandrino-Nicolas, and V. Jornet-Garcia. 2010. Use of antifungal agents for oral candidiasis: results of a national survey. Int. J. Dent. Hyg. 8:47-52.
17. Michna, E., et al. 2004. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J. Pain Symptom Manage. 28:250-258. (Pubitemid 39158807)
18. Neuvonen, M., and P. J. Neuvonen. 2008. Determination of oxycodone, noroxycodone, oxymorphone, and noroxymorphone in human plasma by liquid chromatography-electrospray-tandem mass spectrometry. Ther. Drug Monit. 30:333-340.
19. Niwa, T., S. Inoue-Yamamoto, T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. Biol. Pharm. Bull. 28:1813-1816.
20. Niwa, T., T. Shiraga, and A. Takagi. 2005. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes. Biol. Pharm. Bull. 28:1805-1808.
21. Oliver, R. J., H. S. Dhaliwal, E. D. Theaker, and M. N. Pemberton. 2004. Patterns of antifungal prescribing in general dental practice. Br. Dent. J. 196:701-703.
22. O'Reilly, R. A., et al. 1992. Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects. Clin. Pharmacol. Ther. 51:656-667.
23. Pemberton, M. N., R. J. Oliver, and E. D. Theaker. 2004. Miconazole oral gel and drug interactions. Br. Dent. J. 196:529-531.
24. Pöyhiä, R., K. T. Olkkola, T. Seppälä, and E. Kalso. 1991. The pharmacokinetics of oxycodone after intravenous injection in adults. Br. J. Clin. Pharmacol. 32:516-518.
25. Pöyhiä, R., T. Seppälä, K. T. Olkkola, and E. Kalso. 1992. The pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjects. Br. J. Clin. Pharmacol. 33:617-621.
26. Sistonen, J., S. Fuselli, A. Levo, and A. Sajantila. 2005. CYP2D6 genotyping by a multiplex primer extension reaction. Clin. Chem. 51:1291-1295.
27. Staahl, C., and A. M. Drewes. 2004. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin. Pharmacol. Toxicol. 95:97-111.
28. Stone, B. M. 1984. Pencil and paper tests - sensitivity to psychotropic drugs. Br. J. Clin. Pharmacol. 18(Suppl. 1):15S-20S.